acute myeloid leukemia

[Cancer Cell] Researchers described the stepwise evolution of gilteritinib resistance in FLT3-mutated acute myeloid leukemia. Early resistant cells underwent metabolic reprogramming, grew more slowly, and were dependent upon Aurora kinase B.

[Syndax Pharmaceuticals, Inc.] Syndax Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track Designation to SNDX-5613 for the treatment of adult and pediatric patients with relapsed or refractory acute leukemias harboring a mixed lineage leukemia rearranged or nucleophosmin mutation. SNDX-5613 is the company's highly selective, oral menin inhibitor.

[Cell Death & Disease] Researchers performed a comprehensive analysis for prognostic significance of U2AF1 mutations in acute myeloid leukemia (AML) cohort. Functional analysis of U2AF1S34F mutation was performed in vitro.

[Communications Biology] Midostaurin resistance was overcome by a combination of midostaruin, the BCL-2 inhibitor venetoclax and the RAC1 inhibitor Eht1864 in midostaurin-resistant acute myeloid leukemia (AML) cell lines and primary samples, providing the first evidence of a potential new treatment approach to eradicate FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication + AML.

[Journal of Clinical Oncology] 120 patients with de novo acute myeloid leukemia received either romyelocel-L infusion on day nine with granulocyte colony-stimulating factor (G-CSF) starting daily on day fourteen (treatment group) or G-CSF daily alone on day fourteen (control) until absolute neutrophil count recovery to 500/µL.

[Blood] The authors review the role of the cohesin complex in healthy and malignant hematopoiesis and discuss clinical implications of cohesin mutations in myeloid malignancies and opportunities for therapeutic targeting.